＜Editors' Choice＞ Practice management for elderly patients with breast cancer; Findings from a survey by the Japan Breast Cancer Study Group.

＜Editors' Choice＞ Practice management for elderly patients with breast cancer; Findings from a survey by the Japan Breast Cancer Study Group. Nagoya J Med Sci. 2018 May;80(2):217-226 Authors: Sawaki M, Tamura K, Shimomura A, Taki Y, Nagashima F, Iwata H Abstract Information on patterns of clinical care for elderly breast cancer patients is lacking. The aims of this study are two-fold, firstly, to clarify daily practice treatments for elderly breast cancer patients in Japan, and secondly, to plan a prospective clinical trial to address unresolved clinical questions. We investigated practice care of elderly breast cancer patients in 38 institutions of the Japan Clinical Oncology Group (JCOG). Questionnaires asked: (1) definition of "elderly" for each treatment, (2) clinical standard anti-HER2 therapy in each age-group, (3) recommended docetaxel dose in each age-group, (4) considerations for future clinical trials, and (5) other information about geriatric oncology concerning breast cancer. The upper age-limit for surgery and irradiation therapy was generally 80 years, while many physicians considered anti-cytotoxic adjuvant therapy unsuitable for patients >70-75 years. For HER2-positive metastatic breast cancer, 82% of physicians recommended docetaxel (DTX) plus trastuzumab plus pertuzumab (DTP) as standard care for patients aged 65-70, although 54% of physicians avoided DTP for those aged 71-75 as first-line standard preference...
Source: Nagoya Journal of Medical Science - Category: International Medicine & Public Health Tags: Nagoya J Med Sci Source Type: research